Daniel Karlin, Chief Medical Officer of Definium Therapeutics, Inc. (NASDAQ:DFTX), filed a Form 4 on August 12, 2026, reporting the acquisition of 100,000 common shares at $0.00 as the second tranche of a performance share unit award originally granted effective March 12, 2025.

Key Highlights

  • Reporting person: Daniel Karlin, Chief Medical Officer of Definium Therapeutics, Inc.
  • Transaction date: August 12, 2026, with 100,000 common shares acquired at a price of $0.00.
  • Transaction code: A (acquisition), reported as direct ownership.
  • Resulting ownership: 603,282 common shares beneficially owned directly following the transaction.
  • Award origin: The shares represent the second tranche of performance share units granted effective March 12, 2025.
  • Continued vesting requirement: Shares remain subject to vesting based on continued employment through March 12, 2028.

Details of the Performance Share Unit Award and Vesting Conditions

According to the filing, the 100,000 common shares acquired by Daniel Karlin on August 12, 2026, represent the second tranche of performance share units (PSUs) granted to him effective March 12, 2025. The filing states that each performance share unit represented "a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement." The transaction was recorded at a price of $0.00 per share.

The filing further discloses that the shares "remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028," meaning the award carries an ongoing employment-based condition even after the milestone-triggered issuance. Following the reported transaction, the filing indicates Karlin directly holds 603,282 common shares of Definium Therapeutics, Inc.

The Form 4 was signed by Mark Sullivan as Attorney-in-Fact for Dan Karlin and was filed on August 12, 2026. The filing was made by one reporting person and does not indicate any amendment to a prior form. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

Daniel Karlin, Chief Medical Officer of Definium Therapeutics, Inc. (NASDAQ:DFTX), disclosed the acquisition of 100,000 common shares at $0.00 on August 12, 2026, as a PSU second tranche, bringing his direct beneficial ownership to 603,282 shares.